Last updated: May 30, 2026
HALCION is a brand of triazolam (benzodiazepine hypnotic) marketed in the US for the short-term treatment of insomnia. Triazolam is not a biologic, so there is no biosimilar pathway; competitive risk is primarily generic entry tied to US patent and Orange Book status plus FDA labeling exclusivity (if any).
What is HALCION (triazolam) and what are the latest clinical-trials signals?
HALCION is an oral benzodiazepine hypnotic with established clinical use. No current, high-signal, late-stage (Phase 3) HALCION-specific programs are evident from public trial registries in the same way as for newer sleep agents. The practical “clinical update” for HALCION is mostly incremental: formulation tolerance, insomnia endpoint handling, and safety surveillance, not new efficacy breakthroughs.
What patient populations does HALCION target in clinical research?
Typical clinical-trials inclusion criteria for triazolam-class agents focus on:
- Adults with insomnia characterized by difficulty initiating sleep
- Short-term treatment windows aligned with insomnia trial designs
- Safety monitoring for next-day impairment, sedation, and dependence risks
Which endpoints drive insomnia trials for triazolam-like drugs?
Insomnia trials commonly use:
- Sleep latency (time to persistent sleep)
- Total sleep time
- Wake after sleep onset
- Next-day psychomotor testing
- Patient-reported sleep quality and global improvement scales
What’s the practical meaning of “latest updates” for an established benzodiazepine?
For established products like HALCION, the most actionable “update” is typically:
- Changes in FDA labeling language (Warnings, Dependence, Abuse, Drug Interactions)
- Postmarketing safety signals and risk communications
- Trial activity shifting to comparative studies versus newer hypnotics, often under investigator-led protocols rather than sponsor-led Phase 3
What is the HALCION market size, segment mix, and revenue exposure?
HALCION is an older, off-patent hypnotic relative to newer entrants. In the US, market exposure generally concentrates in:
- Short-term insomnia prescriptions where prescribers still use older benzodiazepine hypnotics
- Cost-sensitive formularies that prefer generics
- Settings where rapid onset and predictable sedation profile fit clinician practice
Which channels capture HALCION demand?
Demand is typically driven by:
- Retail pharmacy scripts
- Chronic-care and primary care prescribing for sleep complaints (often short-term)
- Institutional prescribing in select regions, constrained by formulary controls and safety policies
How does generic erosion typically affect benzodiazepine hypnotics?
For older hypnotics:
- Once multiple generics are on the market, the brand typically becomes a residual share product.
- Brand pricing compresses quickly when wholesale and payer access favors generic equivalents.
- Volumes shift to generics rather than to the brand, unless brand access is retained via contracts or niche payer exclusions.
Where is revenue exposure highest?
Revenue risk is highest where:
- Payer formularies and PBM policies already favor generic alternatives
- Local or national restrictions on benzodiazepine prescribing tighten
- Safety concerns increase utilization of non-benzodiazepine hypnotics
How do HALCION’s patent and exclusivity timelines impact generic entry risk?
HALCION contains triazolam, a small-molecule drug whose initial patent term is far in the past. For the near-term commercialization outlook, the key issue is not new innovation protection but whether any remaining US patents (including formulation, method-of-use, or process patents) still constrain generic competition.
What patents protect HALCION triazolam in the US?
A complete, accurate US patent estate requires current Orange Book listing and patent-by-patent data. With no Orange Book listing content or patent numbers provided in the prompt, a defensible, specific answer cannot be produced.
When does HALCION lose exclusivity?
A specific exclusivity-loss date cannot be stated without:
- Orange Book regulatory listings for triazolam products branded as HALCION (or whichever application corresponds to HALCION)
- Patent expiration dates per listing
- Any FDA exclusivity (non-patent exclusivity) tied to the NDA and listed use
No “latest” timeline can be supplied with integrity under these constraints.
What is the Orange Book status of HALCION (triazolam)?
Orange Book status must be pulled from FDA’s publication of:
- NDA/ANDA identifiers
- Listed patents and their expiration dates
- Exclusivity determinations, if any
- Current applicant (ANDA holders) and whether the brand remains listed as “orphan,” “505(b)(2),” etc.
The prompt provides no Orange Book record details. Without that, an accurate status statement cannot be generated.
What patent litigation affects HALCION generic entry?
Paragraph IV litigation outcomes and settlement-driven “launch windows” depend on:
- Which patents were listed for the specific HALCION NDA
- Which ANDA applicants filed Paragraph IV certifications
- Court docket outcomes (dismissals, stay durations, injunctions)
- Any final judgments or consent decrees
No litigation dataset is included in the prompt. A complete litigation-impact assessment cannot be produced reliably.
What formulations are protected for HALCION, and do they create IP barriers?
For older benzodiazepines, residual IP barriers typically fall into:
- Formulation patents (different release profiles, matrix systems, excipient systems)
- Process patents (manufacturing steps, purification methods)
- Method-of-use patents (specific insomnia subtypes or dosing schedules)
A formulation IP landscape for HALCION requires the listed patents tied to the relevant NDA/ANDA and their claims. No such list is supplied in the prompt.
How does HALCION compare with newer insomnia drugs in clinical and market terms?
In market and prescribing terms, HALCION competes for patients with:
- Non-benzodiazepine “Z-drugs” (e.g., zolpidem, eszopiclone, zaleplon)
- Orexin receptor antagonists (e.g., suvorexant, lemborexant, daridorexant)
- Melatonin receptor agonists and other sedative-hypnotics depending on region and formulary
- Off-label or adjacent therapies (variable by country)
Which clinical differentiators matter for prescribers?
For benzodiazepines like triazolam:
- Rapid onset and anxiolytic/sedative pharmacology
- Clinician familiarity and perceived predictability
- Trade-offs: tolerance, dependence, falls risk, and next-day impairment risk, especially in older patients
In modern insomnia markets, formulary controls increasingly steer use toward agents perceived to have better safety tolerability profiles.
What generic entry risks exist for HALCION?
Generic risk is usually determined by:
- Patent barrier status for triazolam product listings
- Whether any remaining patents cover the brand’s specific dosage form and manufacturing
- Whether FDA has approved multiple ANDAs that effectively compete on price and availability
A defensible generic entry forecast cannot be created without the current Orange Book patent list and ANDA application status.
What is the biosimilar risk for HALCION?
Biosimilars do not apply because HALCION (triazolam) is a small molecule, not a biologic.
Commercial projection for HALCION through 2029
A reliable projection requires at least:
- Baseline brand and generic sales (US and/or key geographies)
- Market share by molecule and by payer segment
- Pricing trends post-generic entry
- Supply availability (who is manufacturing ANDAs)
- Net price and reimbursement environment for hypnotics
No baseline commercial metrics were provided in the prompt, and no public sales dataset is included for extraction. Without those inputs, a numerically grounded forecast would be fabricated.
Key Takeaways
- HALCION is triazolam, a benzodiazepine hypnotic used for short-term insomnia.
- Biosimilar risk is zero because it is a small molecule.
- Competitive pressure is dominated by generic availability and payer formulary controls, not by novel clinical efficacy breakthroughs.
- A specific US patent, Orange Book, exclusivity, Paragraph IV, or litigation-driven entry timeline cannot be stated from the information provided.
- A quantitative market forecast through 2029 cannot be generated without brand and generic sales baselines and pricing/sales data.
FAQs
1) Is HALCION FDA-approved for chronic insomnia?
HALCION labeling is typically framed for short-term use. Chronic use depends on labeling language and clinical practice, which must be verified against the current FDA label for the exact product.
2) Are there HALCION-specific Phase 3 trials currently ongoing?
Ongoing late-stage programs would need confirmation from ClinicalTrials.gov and sponsor registries; no such confirmed dataset is provided in the prompt.
3) Can generic triazolam be substituted for HALCION without restrictions?
Substitution depends on pharmacy substitution laws, formulation equivalence, and payer policies, which vary by jurisdiction.
4) What are the main safety risks that limit use of triazolam products?
Benzodiazepine hypnotics class risks include dependence, withdrawal, next-day impairment, and falls or cognitive effects, with heightened concern in older adults.
5) How do payer restrictions typically impact benzodiazepine hypnotic sales?
Prior authorization, quantity limits, step therapy, and safety monitoring policies can reduce utilization and shift patients toward preferred alternatives.
References
(No sources cited because the prompt did not provide Orange Book, FDA label, ClinicalTrials.gov identifiers, litigation dockets, or sales datasets, and no external documents were included for extraction.)
